Establishes HPLC for simultaneous analysis of compounds in nanoethosomal carriers, suggesting improved quality control.
The development of robust analytical methods is essential for quality control of nanoethosomal formulations containing asiaticoside and α-mangostin, bioactive compounds with anti-inflammatory and antioxidant properties. Simultaneous quantification within nanocarriers is challenging and requires validated techniques. This study established a precise HPLC method, in accordance with ICH Q2(R2) guidelines, for the concurrent determination of both compounds. The technique demonstrated excellent linearity (R2 > 0.999), precision (%RSD < 2%), and accuracy (95–105% recovery). The nanoethosomal system also achieved high encapsulation efficiencies of 94.76% for asiaticoside and 99.27% for α-mangostin. This validated method provides a reliable tool for standardizing these complex nano-formulations, supporting their further development and clinical translation.
No takes yet. Share an insight, caveat, or question.
Aswan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: